International Journal of Clinical Oncology

, Volume 23, Issue 2, pp 375–381 | Cite as

Retrospective analysis of first-line treatment for follicular lymphoma based on outcomes and medical economics

  • Manaka Muneishi
  • Ayaka Nakamura
  • Katsumi Tachibana
  • Junko Suemitsu
  • Shinji Hasebe
  • Kazuto Takeuchi
  • Yoshihiro Yakushijin
Original Article
  • 167 Downloads

Abstract

Background

Follicular lymphoma (FL) is the most common type of non-Hodgkin lymphoma (NHL), with indolent progression. Several treatment options are selected, based not only on disease status, quality of life (QOL), and age of patient, but also on recent increasing medical costs. We retrospectively analysed the first-line treatment of FL with regard to treatment outcomes and medical economics, and discuss the appropriate strategies for FL.

Methods

Data on a total of 69 newly-diagnosed patients with FL was retrospectively collected from 2001 to 2015.

Results

The median age of the patients was 60 years and the median follow-up was 58 months. A total of 25 cases with FL were treated with R monotherapy, and 28 cases were treated with R-CHOP as first-line treatment. The factors affecting the decision of physicians to use R or R-CHOP treatment were serum level of lactate dehydrogenase (LDH) and disease stage. The first-line treatment-associated survival did not show any statistical differences between R and R-CHOP. The average hospitalization and average of all medical costs during the first-line treatment were 4.1 days (R) versus 55.7 days (R-CHOP), and JPY 1,707,693 (USD 15,324) (R) versus JPY 2,136,117 (USD 19,170) (R-CHOP), respectively.

Conclusion

R monotherapy for patients whose diseases show low tumor burden and who are not candidates for local treatment has benefits as a first-line treatment compared to R-CHOP, based on the patients’ QOL and medical economics.

Keywords

Rituximab Follicular lymphoma Medical economics 

Notes

Acknowledgements

We appreciate the cooperation of the staff members of the chemotherapy room in Ehime University Hospital.

Compliance with ethical standards

Conflict of interest

The authors have no conflict of interest.

References

  1. 1.
    Lo Coco F, Gaidano G, Louie DC et al (1993) P53 mutations are associated with histologic transformation of follicular lymphoma. Blood 82:2289–2295PubMedGoogle Scholar
  2. 2.
    Elenitoba-Johnson KS, Gascoyne RD, Lim MS et al (1998) Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma. Blood 91:4677–4685PubMedGoogle Scholar
  3. 3.
    Pinyol M, Cobo F, Bea S et al (1998) P16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin’s lymphomas. Blood 91:2977–2984PubMedGoogle Scholar
  4. 4.
    Lossos IS, Alizadeh AA, Diehn M et al (2002) Transformation of follicular lymphoma to diffuse large-cell lym-phoma: alternative patterns with increased or decreased expression of c-myc and its regulated genes. Proc Natl Acad Sci USA 99:8886–8891CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Akasaka T, Lossos IS, Levy R (2003) BCL6 gene translocation in follicular lymphoma: a harbinger of eventual transformation to diffuse aggressive lymphoma. Blood 102:1443–1448CrossRefPubMedGoogle Scholar
  6. 6.
    Brodtkorb M, Lingjaerde OC, Huse K et al (2014) Whole-genome integrative analysis reveals expression signatures predicting transformation in follicular lymphoma. Blood 123:1051–1054CrossRefPubMedGoogle Scholar
  7. 7.
    Vasishtha M, Messina M, Holmes AB et al (2014) Genetics of follicular lymphoma transformation. Cell Rep 6:130–140CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Bai B, Huang HQ (2015) Individualized management of follicular lymphoma. Chin Clin Oncol 4:7. doi: 10.3978/j.issn.2304-3865.2015.01.01 PubMedGoogle Scholar
  9. 9.
    Izutsu K (2014) Treatment of follicular lymphoma. J Clin Exp Hematop 54:31–37CrossRefPubMedGoogle Scholar
  10. 10.
    Hiddemann W, Cheson BD (2014) How we manage follicular lymphoma. Leukemia 28:1388–1395CrossRefPubMedGoogle Scholar
  11. 11.
    Kenkre VP, Kahl BS (2012) What is the best initial therapy for a patient with symptomatic low-grade follicular lymphoma? Cancer J 18:383–389CrossRefPubMedGoogle Scholar
  12. 12.
    Bello C, Zhang L, Naghashpour M (2012) Follicular lymphoma: current management and future directions. Cancer Control 19:187–195CrossRefPubMedGoogle Scholar
  13. 13.
    Salles G, Ghesquières H, Bachy E (2012). What is the best first-line treatment strategy for patients with indolent lymphomas? Am Soc Clin Oncol Educ Book, pp 488–493Google Scholar
  14. 14.
    McLaughlin P (2011) Management options for follicular lymphoma: observe; R-CHOP; B-R; others? Clin Lymphoma Myeloma Leuk 11(Suppl 1):S91–S95. doi: 10.1016/j.clml.2011.04.006 CrossRefPubMedGoogle Scholar
  15. 15.
    van Agthoven M, Kramer MH, Sonneveld P et al (2005) Cost analysis of common treatment options for indolent follicular non-Hodgkin’s lymphoma. Haematologica 90:1422–1432PubMedGoogle Scholar
  16. 16.
    Schmitz S, Aly F, Steinmetz T et al (2006) Sensitivity analysis of cost factors for various therapy options in the treatment of follicular lymphoma. Onkologie 29:258–264PubMedGoogle Scholar
  17. 17.
    Soini EJ, Martikainen JA, Vihervaara V et al (2012) Economic evaluation of sequential treatments for follicular non-Hodgkin lymphoma. Clin Ther 34:915–925CrossRefPubMedGoogle Scholar
  18. 18.
    Johnston KM, Bolbocean C, Connors J et al (2012) Cost-effectiveness of rituximab in follicular lymphoma. Expert Rev Pharmacoecon Outcomes Res 12:569–577CrossRefPubMedGoogle Scholar
  19. 19.
    Prica A, Chan K, Cheung M (2015) Frontline rituximab monotherapy induction versus a watch and wait approach for asymptomatic advanced-stage follicular lymphoma: a cost-effectiveness analysis. Cancer 121:2637–2645CrossRefPubMedGoogle Scholar
  20. 20.
    Danese MD, Reyes CM, Gleeson ML et al (2016) Estimating the population benefits and costs of rituximab therapy in the United States from 1998 to 2013 using real-world data. Med Care 54:343–349CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Solal-Céligny P, Roy P, Colombat P et al (2004) Follicular lymphoma international prognostic index. Blood 104:1258–1265CrossRefPubMedGoogle Scholar
  22. 22.
    Milanovic N, Matkovic S, Ristic D et al (2012) Significance of tumor burden, vascular endothelial growth factor, lactate dehydrogenase and beta-2 microglobulin serum levels in advanced diffuse large B cell lymphoma. J BUON 17:497–501PubMedGoogle Scholar
  23. 23.
    Kahl BS, Hong F, Williams ME et al (2014) Rituximab extended schedule or re-treatment trial for low tumor burden follicular lymphoma: Eastern Cooperative Oncology Group protocol E4402. J Clin Oncol 32:3096–3102CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Palla AR, Hamadani M (2013) Rituximab maintenance versus retreatment in follicular lymphoma. Hematol Oncol 31:171–178CrossRefPubMedGoogle Scholar
  25. 25.
    Johnston A, Bouafia-Sauvy F, Broussais-Guillaumot F et al (2009) Retreatment with rituximab in 178 patients with relapsed and refractory B-cell lymphomas: a single institution case control study. Leuk Lymph 51:399–405CrossRefGoogle Scholar
  26. 26.
    Rummel MJ, Niederle N, Maschmeyer G et al (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381:1203–1210CrossRefPubMedGoogle Scholar
  27. 27.
    Flinn IW, van der Jagt R, Kahl BS et al (2014) Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 123:2944–2952CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2017

Authors and Affiliations

  1. 1.Department of Clinical OncologyEhime University School of MedicineToonJapan
  2. 2.Medical Profession DivisionEhime University HospitalToonJapan
  3. 3.Department of Clinical OncologyEhime University Graduate School of MedicineToonJapan
  4. 4.Cancer CenterEhime University HospitalToonJapan

Personalised recommendations